ProCE Banner Activity

CheckMate 648 Update: Phase III Study of First-line Nivolumab + CT vs Nivolumab + Ipilimumab vs CT for Advanced Esophageal Squamous Cell Carcinoma

Conference Coverage

With 29 months of follow-up, both nivolumab + chemotherapy and nivolumab + ipilimumab continued to demonstrate clinically meaningful OS benefit compared with chemotherapy alone in previously untreated patients with advanced esophageal SCC.

Released: February 02, 2023

Expiration: February 01, 2024


Provided by

ProCE Banner


Bristol Myers Squibb

Incyte Corporation

Seagen Inc.